Research Reports

Key takeaways

Christopher Gibson, Ph.D., informed the Company on April 28, 2026, that he will not stand for re-election as a Class II Director.

Gibson will continue as Chair of the Board and serve on committees until his term expires at the 2026 Annual Meeting.

The decision was not the result of any disagreement with the Company regarding operations, policies, or practices.

Gibson will remain with the Company as a strategic advisor following the expiration of his Board term.

Najat Khan, Ph.D., CEO, and Rob Hershberg, M.D., Ph.D., Vice-Chair, praised Gibson's contributions and partnership.

Full analysis

Christopher Gibson, Ph.D., co-founder and Chair of the Board, notified Recursion Pharmaceuticals on April 28, 2026, that he will not seek re-election as a Class II Director at the upcoming 2026 Annual Meeting. His current term is set to expire in June 2026. The filing explicitly states that his departure is not due to any disagreement with the Company’s operations, policies, or practices. Dr. Gibson will maintain his positions as Chair and member of the Research and Development, Technology, and Corporate Social Responsibility Committees until the annual meeting. Following his Board departure, he will transition to a strategic advisor role, ensuring continuity for the clinical-stage TechBio company.

RXRX · Recursion Pharmaceuticals, Inc.

Summary

Key takeaways

Full analysis